Skip to main content

Table 2 Clinical outcomes after atorvastatin treatment or placebo

From: Effects of short-term treatment with atorvastatin in smokers with asthma - a randomized controlled trial

Variables

Baseline

4 weeks

†Treatment difference,

atorvastatin minus

placebo (95% CI)

8 weeks

†Treatment difference,

atorvastatin minus

placebo (95% CI)

 

Atorvastatin

(n = 36)

Placebo

(n = 32)

Atorvastatin

(n = 34)

Placebo

(n = 30)

 

Atorvastatin & ICS

(n = 33)

Placebo & ICS

(n = 27)

 

Morning PEF L/min

381.33

(138.79)

348.99

(116.49)

376.39

(141.63)

357.65

(121.38)

-10.67

(-38.70, 17.37)

p = 0.449

390.51

(123.38)

354.64

(123.70)

10.68

(-20.29, 41.65)

p = 0.492

Evening PEF L/min

391.9

(137.1)

375.8

(118.4)

384.8

(137.1)

367.4

(117.2)

4.95

(-18.61, 28.51)

p = 0.676

400.0

(140.1)

368.3

(130.5)

25.03

(-2.04, 52.11)

p = 0.069

FEV 1 pre-salbutamol, L

2.76

(0.91)

2.51

(0.76)

2.79

(0.83)

2.59

(0.74)

-0.01

(-0.13, 0.11)

p = 0.872

2.80

(0.89)

2.63

(0.76)

0.03

(-0.10, 0.16)

p = 0.651

FEV 1 post-salbutamol, L

3.08

(0.94)

2.88

(0.75)

3.02

(0.88)

2.89

(0.75)

-0.03

(-0.13, 0.07)

p = 0.492

3.02

(0.90)

2.93

(0.74)

-0.02

(-0.12, 0.07)

p = 0.642

PC 20 methacholine

geometric mean, mg/ml

3.29

(4.03)

2.15

(3.34)

4.12

(4.86)

2.93

(5.0)

1.36

(-1.29, 4.01)

p = 0.307

5.31

(6.2)

2.31

(4.0)

1.37

(-0.65, 3.40)

p = 0.179

ACQ Score

[6 questions]

1.86

(1.02)

1.86

(0.82)

1.42

(0.68)

1.91

(1.10)

-0.48

(-0.84,-0.12)

p = 0.009

1.29

(0.93)

1.64

(1.10)

-0.37

(-0.8,0.07)

p = 0.096

ACQ score

[7 questions]

1.88

(1.00)

1.96

(0.79)

1.50

(0.67)

1.90

(0.90)

-0.37

(-0.67, -0.07)

p = 0.016

1.38

(0.93)

1.77

(1.00)

-0.35

(-0.74, 0.04)

p = 0.081

AQLQ

Total score

5.36

(1.05)

5.14

(1.14)

5.71

(0.83)

5.04

(1.30)

0.52

(0.17, 0.87)

p = 0.005

5.79

(1.02)

5.27

(1.34)

0.37

(-0.02, 0.76)

p = 0.063

AQLQ Symptoms Domain

4.96

(1.08)

4.82

(1.20)

5.46

(0.90)

4.74

(1.39)

0.63

(0.18, 1.09)

p = 0.007

5.67

(4.96,6.34)

4.88

(3.91,6.5)

0.42

(-0.05, 0.89)

p = 0.082

AQLQ Activity Limitations Domain

5.84

(1.06)

5.52

(1.15)

5.99

(0.90)

5.36

(1.25)

0.40

(0.10, 0.71)

p = 0.010

6.08

(0.97)

5.58

(1.29)

0.31

(-0.01, 0.63)

p = 0.061

AQLQ Emotional Functions Domain

5.51

(1.36)

5.10

(1.35)

5.90

(1.19)

5.02

(1.62)

0.60

(0.10, 1.09)

p = 0.019

5.87

(1.39)

5.30

(1.62)

0.24

(-0.26, 0.74)

p = 0.335

AQLQ Environmental Stimuli Domain

5.10

(1.30)

5.09

(1.33)

5.41

(1.18)

5.07

(1.44)

0.34

(-0.09, 0.77)

p = 0.123

5.71

(1.15)

5.13

(1.47)

0.55

(0.07, 1.03)

p = 0.026

Reliever inhaler puffs per 24 hrs

3.19

(2.55)

2.94

(2.93)

2.58

(2.67)

3.97

(5.45)

-0.66

(-1.69, 0.37)

p = 0.205

2. 13

(2.63)

1.99

(2.33)

-0.12

(-1.35, 1.11)

p = 0.841

  1. Abbreviations: ACQ, Asthma Control Questionnaire; AQLQ, Asthma Quality of Life Questionnaire; PEF, peak expiratory flow rate; FEV1, forced expiratory volume in one second; Data represented as mean (SD) unless otherwise indicated.
  2. †Treatment difference from analysis of covariance, analysing change from baseline and adjusting for baseline value.
Back to article page

BMC Pulmonary Medicine

ISSN: 1471-2466

Contact us